Moderna pauses norovirus vaccine trial after missing interim analysis

Moderna announced it will not enroll a new cohort in the phase 3 trial of its mRNA-1403 norovirus vaccine.

The decision follows a July interim analysis that showed the vaccine missed its predefined endpoints.

Company officials said they will meet with health authorities to discuss possible next steps and will provide updates after those discussions.

The move coincided with a 27% drop in R&D spending to $583 million in the third quarter, reflecting the program's setback.